azasetron has been researched along with Neoplasms in 4 studies
azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration." | 9.14 | Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan." | 9.08 | [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996) |
| "Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration." | 5.14 | Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009) |
| "BNT used in coordination with Azasetron for alleviating vomiting could enhance the antiemetic effect, reduce the adverse effects of chemotherapy, such as constipation, abdominal distension and anorexia, and thus to increase the compliance of patients." | 5.12 | [Clinical efficacy of Bannaitong Mdicinal Tea combined with azasetron in preventing and treating chemotherapy induced gastrointestinal reaction]. ( Li, GL; Li, YW, 2007) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan." | 5.08 | [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, L | 1 |
| Liu, J | 1 |
| Liu, X | 1 |
| Chen, J | 1 |
| Yan, Z | 1 |
| Yang, H | 1 |
| Zhang, D | 1 |
| Li, GL | 1 |
| Li, YW | 1 |
| Okuyama, K | 1 |
| Yoshimoto, K | 1 |
| Iwase, O | 1 |
| Ozeki, T | 1 |
| Yamada, Y | 1 |
| Kimura, E | 1 |
| Niimi, S | 1 |
| Watanabe, A | 1 |
| Akiyama, M | 1 |
| Tanaka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting[NCT02970643] | 48 participants (Anticipated) | Interventional | 2016-07-31 | Enrolling by invitation | |||
| Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent Nausea and Vomiting Induced by Chemotherapy：:A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial[NCT05805800] | Phase 3 | 238 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911] | Phase 3 | 120 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 15 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 17 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Aprepitant Regimen | 15 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）" (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 18 |
| Control Regimen | 15 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 7 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 6 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 41 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 35 |
| Control Regimen | 40 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 31 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 30 |
3 trials available for azasetron and Neoplasms
| Article | Year |
|---|---|
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
[Clinical efficacy of Bannaitong Mdicinal Tea combined with azasetron in preventing and treating chemotherapy induced gastrointestinal reaction].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, He | 2007 |
[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; | 1996 |
1 other study available for azasetron and Neoplasms
| Article | Year |
|---|---|
[Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimi | 2008 |